A significant change in the definition of core basis in the financial results was observed. Astellas seeks approval for eye drug Izervay in Europe and Japan and has also initiated research collaborations with Poseida Therapeutics and Elpiscience. The company also opens a new aseptic drug product manufacturing facility in Ireland. The US FDA approves Astellas' bladder cancer combination therapy while declining approval for its gastric cancer drug. Astellas continues to focus on patient-centric healthcare with collaborations with YASKAWA and Eko Health. Despite a miss in analysts' earnings estimates, the company maintains a promising outlook with multiple research and development projects, investments, and partnerships underway. Potential setbacks include a lawsuit withdrawal against Medicare drug price negotiation plans and the arrest of an employee in China on suspicion of spying. Despite these challenges, the company continues its commitment to developing innovative healthcare solutions.
Astellas Pharma Inc. News Analytics from Mon, 15 Oct 2018 13:10:26 GMT to Tue, 11 Jun 2024 01:33:00 GMT - Rating 5 - Innovation 8 - Information 7 - Rumor -4
